{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:18:18Z","timestamp":1786997898264,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","issue":"37","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009898","name":"Defense Health Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009898","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014058","name":"Bureau of Medicine and Surgery","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014058","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.vaccine.2020.06.073","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T17:34:17Z","timestamp":1595439257000},"page":"5933-5939","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Maternal and infant outcomes following exposure to quadrivalent human papillomavirus vaccine during pregnancy"],"prefix":"10.1016","volume":"38","author":[{"given":"Anna T.","family":"Bukowinski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clinton","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard N.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gia R.","family":"Gumbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava","family":"Marie S. Conlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.06.073_b0005","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1363\/3600604","article-title":"Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000","volume":"36","author":"Weinstock","year":"2004","journal-title":"Perspect Sex Reprod Health"},{"key":"10.1016\/j.vaccine.2020.06.073_b0010","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1542\/peds.2009-0674","article-title":"Prevalence of sexually transmitted infections among female adolescents aged 14 to 19 in the United States","volume":"124","author":"Forhan","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2020.06.073_b0015","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.297.8.813","article-title":"Prevalence of HPV infection among females in the United States","volume":"297","author":"Dunne","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2020.06.073_b0020","first-page":"1","article-title":"Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Markowitz","year":"2014","journal-title":"MMWR Recomm Rep"},{"issue":"156","key":"10.1016\/j.vaccine.2020.06.073_b0025","first-page":"e1","article-title":"Late recognition of pregnancy as a predictor of adverse birth outcomes","volume":"201","author":"Ayoola","year":"2009","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2020.06.073_b0030","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1097\/AOG.0b013e3181c2a122","article-title":"Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6\/11\/16\/18 vaccine","volume":"114","author":"Dana","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2020.06.073_b0035","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1016\/j.vaccine.2015.04.014","article-title":"Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine","volume":"33","author":"Goss","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.073_b0040","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1345\/aph.1P396","article-title":"Safety of the HPV bivalent and quadrivalent vaccines during pregnancy","volume":"45","author":"Forinash","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.vaccine.2020.06.073_b0045","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.vaccine.2014.11.047","article-title":"Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006\u20132013","volume":"33","author":"Moro","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.073_b0050","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1080\/21645515.2016.1160178","article-title":"Is HPV vaccination in pregnancy safe?","volume":"12","author":"Bonde","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.06.073_b0055","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/AOG.0b013e3181c2ca21","article-title":"Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6\/11\/16\/18 vaccine: a combined analysis of five randomized controlled trials","volume":"114","author":"Garland","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2020.06.073_b0060","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/AOG.0000000000002191","article-title":"Maternal and infant outcomes after human papillomavirus vaccination in the periconceptional period or during pregnancy","volume":"130","author":"Lipkind","year":"2017","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2020.06.073_b0065","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1056\/NEJMoa1612296","article-title":"Quadrivalent HPV vaccination and the risk of adverse pregnancy outcomes","volume":"376","author":"Scheller","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.06.073_b0070","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.vaccine.2018.11.030","article-title":"Adverse pregnancy outcomes and infant mortality after quadrivalent HPV vaccination during pregnancy","volume":"37","author":"Faber","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.073_b0075","unstructured":"US Department of the Air Force. Human Papillomavirus Vaccination Policy [memorandum, SG3 DOC 07-036]. Washington, DC: April 13, 2007. https:\/\/health.mil\/Reference-Center\/Policies\/2007\/04\/13\/Human-Papillomavirus-Vaccination-Policy."},{"key":"10.1016\/j.vaccine.2020.06.073_b0080","series-title":"Provisional Recommendations on Use of the Quadrivalent Human Papillomavirus (HPV) Vaccine","author":"US Department of the Army","year":"2007"},{"key":"10.1016\/j.vaccine.2020.06.073_b0085","unstructured":"US Department of the Navy. Recommendations for the Use of the Quadrivalent HPV Vaccine in Female Navy and Marine Corps Beneficiaries [NAVMED Policy 07-017]. Washington, DC: Navy Bureau of Medicine and Surgery, May 17, 2007. https:\/\/www.med.navy.mil\/sites\/nmcphc\/Documents\/health-promotion-wellness\/reproductive-and-sexual-health\/navy-medicine-hpv-vaccination-policy.pdf."},{"key":"10.1016\/j.vaccine.2020.06.073_b0090","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1056\/NEJMsa1506575","article-title":"Declines in unintended pregnancy in the United States, 2008\u20132011","volume":"374","author":"Finer","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.06.073_b0095","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/AOG.0b013e318280d64e","article-title":"Crum-Cianflone NF. Safety of the pandemic H1N1 influenza vaccine among pregnant U.S. military women and their newborns","volume":"121","author":"Conlin","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2020.06.073_b0100","first-page":"39","article-title":"Department of Defense Birth and Infant Health Registry: select reproductive health outcomes, 2003\u20132014","volume":"24","author":"Bukowinski","year":"2017","journal-title":"MSMR"},{"key":"10.1016\/j.vaccine.2020.06.073_b0105","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/pds.4153","article-title":"Identifying birth defects in automated data sources in the Vaccine Safety Datalink","volume":"26","author":"Kharbanda","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2020.06.073_b0110","series-title":"Guidelines for conducting birth defects surveillance","article-title":"Birth defects descriptions for NBDPN core, recommended, and extended conditions","author":"National Birth Defects Prevention Network","year":"2004"},{"key":"10.1016\/j.vaccine.2020.06.073_b0115","first-page":"1","article-title":"Trend analysis of the sex ratio at birth in the United States","volume":"53","author":"Mathews","year":"2005","journal-title":"Natl Vital Stat Rep"},{"key":"10.1016\/j.vaccine.2020.06.073_b0120","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/aje\/kwh090","article-title":"A modified Poisson regression approach to prospective studies with binary data","volume":"159","author":"Zou","year":"2004","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2020.06.073_b0125","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/AOG.0000000000002694","article-title":"Risk of spontaneous abortion after inadvertent human papillomavirus vaccination in pregnancy","volume":"132","author":"Kharbanda","year":"2018","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2020.06.073_b0130","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1586\/14760584.2014.867236","article-title":"Is administration of the HPV vaccine during pregnancy feasible in the future?","volume":"13","author":"Berenson","year":"2014","journal-title":"Exp Rev Vacc"},{"key":"10.1016\/j.vaccine.2020.06.073_b0135","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/infdis\/jiy682","article-title":"Human papillomavirus vaccination before 13 and 15 years of age: analysis of National Immunization Survey Teen data","volume":"220","author":"Bednarczyk","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.06.073_b0140","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev.med.59.092806.131644","article-title":"Appropriate use of cervical cancer vaccine","volume":"59","author":"Zimet","year":"2008","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.vaccine.2020.06.073_b0145","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12593","article-title":"Is HPV vaccination of pregnant women really safe?","volume":"31","author":"Feily","year":"2018","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.vaccine.2020.06.073_b0150","doi-asserted-by":"crossref","first-page":"3086036","DOI":"10.1155\/2016\/3086036","article-title":"Human papillomavirus infection as a possible cause of spontaneous abortion and spontaneous preterm delivery","volume":"2016","author":"Ambuhl","year":"2016","journal-title":"Infect Dis Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2020.06.073_b0155","first-page":"69","article-title":"Validating the use of ICD-9-CM codes to evaluate gestational age and birth weight","volume":"39","author":"Barrett","year":"2012","journal-title":"J Registry Manag"},{"key":"10.1016\/j.vaccine.2020.06.073_b0160","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/aje\/kwk027","article-title":"Conditions for bias from differential left truncation","volume":"165","author":"Howards","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2020.06.073_b0165","unstructured":"Gardasil 9 [package insert]. Kenilworth, NJ: Merck & Co., Inc.; 2018."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20308768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20308768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:45:22Z","timestamp":1759401922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20308768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":33,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0264410X20308768"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.06.073","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maternal and infant outcomes following exposure to quadrivalent human papillomavirus vaccine during pregnancy","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.06.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}